Form 4 for OLMA Olema Pharmaceuticals, Inc.
Accepted 2021-12-14 00:00:00 ET · period of report 2021-12-10 · accession 0001415889-21-005860 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-14 | 2021-12-10 | OLMA | Myles David C. | Chief DEVELOPMENT Off | S - Sale | $10.30 | -10.0K | 582.9K | -2% | -$103.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-10 | S | D | 10,000 | $10.30 | 582,901 | D | — | — | (F1) T he weighted average sale price for the transaction reported was $10.30, and the range of prices was between $10.23 and $10.50. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. (F2) Includes 589 shares acquired under the issuer's Employee Stock Purchase Plan on May 14, 2021, and 491 shares acquired under the issuer's Employee Stock Purchase Plan on November 15, 2021. |